Simulations Plus Receives New FDA Grant Award (09/21/2023) Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment (08/15/2023) Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses (04/18/2023) Simulations Plus Enters New Strategic Collaboration to Discover Anticancer…
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities (06/20/2023)
Third annual conference on model-informed drug development strategies from discovery through post-approval phases. Watch Session Replays
Amparo de la Peña elected to the International Society of Pharmacometrics (ISoP) Board of Trustees (11/08/2023) Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS) (08/24/2023) Peter Kilford joins Simulations Plus (Formerly Labcorp Drug Development, Certara)…
Simulations Plus Releases ADMET Predictor® 11 (7/13/23) Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite(TM) in Version 2023R1 (3/28/23) Simulations Plus Rleases Redesigned NAFLDsym v2B (2/9/23) Simulations Plus Release DILIsym X (1/12/23)
Strong growth, innovation, and global reach drive the company’s progress. Read More
Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials. Read More
Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits. Learn More
“We are very proud and humbled by our achievements at SLP over these past 25 years and look forward to celebrating this milestone over the next year with our clients, employees, and collaborators,” said Shawn O’Connor, CEO. Learn More
Gustavo Mendez Lima Santos Joins Simulations Plus (Formerly Anvisa, Brazil) (11/3/22) Renée Bouché celebrates 21 years at Simulations Plus (10/29/22) Frederico Martins Joins Simulations Plus (Formerly esqLABS, Galapagos Pharmaceuticals, Certara) (10/24/22) Xavier Pepin Joins Simulations Plus (Formerly AstraZeneca & Sanofi) (5/2/22) Anant Ketkar Joins Simulations…
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code (11/3/22) Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer (7/21/22) Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare…
Improving Health Through Innovative Solutions in Model-Based Drug Discovery. Watch Session Replays
Providing one-on-one support for our clients and partners as they navigate the long and winding road of model-informed drug discovery. Learn More
Simulations Plus and the University of Bath Awarded New FDA Grant (11/15/22) Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products (11/2/22) Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization…
Simulations Plus Releases GastroPlus® Version 9.8.3 (10/12/22) Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease (8/31/22) Simulations Plus Releases ADMET Predictor Version 10.4 (X.4) (5/26/22) Simulations Plus Releases MembranePlus 3.0 (3/10/22) Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1 (1/5/22)
Expanding access to high-quality medication for people in need Read More
In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About Her Journey
In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About His Journey
Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More
Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More